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from timepoint to timepoint. Stacked cumulative percent plots can be applied to 
diverse disease types and to outcomes with varying amounts of anticipated change 
from timepoint to timepoint.
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OBJECTIVES: The aim of the study is to utilize the novel frontier analysis to 
search for optimal strategy of vaccination policy against infectious diseases with
limited vaccine supply. METHODS: An important goal of public health research 
is to predict clinical impact by nation-wide mass vaccination in preventing infectious 
diseases. Vaccination is usually given across potential vulnerable populations such 
as children. However, due to limited resources provided by the government among
a growing number of competing vaccine products, some vaccinations are to be given
to some targeted high-risk cohorts against infectious diseases, such as pneumonia 
or inﬂ uenza. Hence, the optimal strategy of vaccination policy for effective disease 
control becomes a practical concern. We propose a model using frontier analysis 
to seek the optimal vaccination policy in controlling infectious disease epidemics
with limited resources. The problem is initially formulated to ﬁ nd the maximal life 
years gained while minimizing the variance. Various vaccination policies were
explored in ﬁ nding the optimal vaccination strategy. The indirect effects on unvacci-
nated cohorts were also considered in the analysis. The technique is illustrated using 
pneumococcal conjugate vaccine (PCV) in Taiwan as an example. RESULTS: Using
the empirical study of PCV and various scenarios of the policy with limited resource,
we provide the best vaccination strategy among various deﬁ ned cohorts and report
the maximal life years gained with the ﬁ xed total cost of the vaccine given. Our study
can be generalized to the optimization of vaccination strategies for most infectious 
diseases among different population structures. CONCLUSIONS: When disease
burden is high, more emphasis should be laid on the possible health beneﬁ ts gained
with a vaccination program, instead of just considering the economic beneﬁ ts. Our
study can help to guide decision makers in determining optimal uses of limited
quantities of vaccine across multiple targeted cohorts to effectively control infectious
diseases.
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OBJECTIVES: The goal of asthma management is to gain and maintain control. 
Several validated patient-reported measures are available to assess the degree of 
control: Asthma Control Questionnaire (ACQ), Asthma Control Test (ACT), and the 
Asthma Therapy and Assessment Questionnaire (ATAQ). We propose a ﬂ exible and 
transparent model structure that represents disease variability through exacerbation
rates and any one of the three control instruments. METHODS: We developed a 
Markov model to simulate cohorts transitioning among six health states: an asthma 
control continuum state (variability in control is tracked using one of the three control 
instruments), three severity levels of asthma exacerbation, and asthma and non-asthma
related death. To estimate the cost and outcome weights for the control continuum 
state, we explored the relationship between the ATAQ (higher ATAQ  less control) 
and management costs (including absenteeism costs) and utilities using a large asthma
registry of exacerbation-free patients. A hypothetical asthma intervention added to 
standard-of-care was compared to standard-of-care alone as summarized by the fol-
lowing product proﬁ le: a 50% reduction in asthma exacerbation rates, a 0.5 absolute
improvement in the ATAQ score, and an additional $10,000 per annum intervention 
cost. RESULTS: The estimated change in bi-weekly asthma management costs for a 
one unit increase in the ATAQ score was $36.12 (robust SE  $3.95) and for utilities
was 0.05 (robust SE  0.0041). Assuming a ﬁ ve year time horizon, the hypothetical 
intervention plus standard-of-care had an incremental mean cost of $25,800 (95% 
interval $10,600, $41,000), quality adjusted life year (QALY) of 0.257 (0.106, 0.435), 
and cost per QALY of $100,500/QALY ($13,700, $199,800). CONCLUSIONS: As 
relationships emerge between any of the instruments of control and costs and utilities,
this versatile model can forecast: long-term burden of disease, value of existing and
emerging interventions, and inputs that yield the highest return from further study.
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Identity, the view of self-reference, is not static across populations and is probably not
stable within an individual over time. Philosophers, psychologists and the religious
continue to offer support for particular points of view of identity but there are many 
differences among them. These differences seem quite able to bias utility and patient-
reported outcomes assessments. As such, care must be taken to understand the self-
reference schemas of the population within which self-assessments are validated and
used. Some of the options people have and use for self-reference are: 1. operational
(e.g., I am a clinical researcher or a father), 2. preference-oriented (e.g., I am a lover 
of wine or a “runner”), 3. physical (e.g., I am my body), 4. psychological (e.g., I am 
my ego), 5. religious (e.g., I am spirit) and 6. philosophical (e.g., I am thinking, I am
consciousness, no such thing as identity exists, I am subjective experience). It’s surpris-
ing self-assessments are conducted when we don’t know who is responding to our
questions. The confound of identity is important to study in its own right because of 
how strongly it can inﬂ uence public policy through research ﬁ ndings based on self-
assessments. “View of self-reference” seems a fundamental and necessary element for
inclusion into requirements for construction and validation of PROs. Otherwise, 
instrument bias could be speciﬁ cally used to make a certain claim, much like regression 
towards the mean could be used if it was not previously identiﬁ ed as a threat to valid-
ity. That identify may shift over time within an individual, say from an external focus 
to an internal focus, may be the reason why some terminally ill patients report good 
quality of life despite their poor health. When the body is not a factor in one’s identity, 
what is the meaningfulness of health-related quality of life anyway?
PMC6
META–REGRESSION AS A METHOD OF IDENTIFICATION OF THE
CAUSES OF HETEROGENEITY BETWEEN STUDIES ON THE EXAMPLE
OF RELATIONSHIP BETWEEN SURROGATES AND CLINICALLY
IMPORTANT ENDPOINTS IN TYPE–2 DIABETES MELLITUS
Marcisz A1, Rys P2, Wieczorek A1, Plisko R2, Wladysiuk M1, Skrzekowska-Baran I3
1HTA Consulting, Krakow, Malopolska, Poland, 2HTA Consulting, Krakow, Poland, 3Novo 
Nordisk, Inc., Warsaw, Mazowieckie, Poland
OBJECTIVES: Use of meta-regression to explain heterogeneity between the studies
evaluating relationship between the level of glycated hemoglobin (HbA1c) and the risk 
of development of retinopathy in patients with type 2 diabetes mellitus (DMT2). In 
meta-regression the results of the studies under consideration are treated as points to 
be analyzed by weighted regression. If the results obtained in a model without covari-
ates indicate heterogeneity of studies, then inclusion of subsequent covariates into the
model can make it possible to check if speciﬁ c variables explain heterogeneity. The
amount of heterogeneity may be expressed as between-study variance. If between-
study variance decreases after inclusion of a speciﬁ c covariate into the model, it means
that heterogeneity between the studies may be explained by that covariate. METHODS:
The following covariates were considered: observation period, type of the study, 
sample size, HbA1c level, age, duration of DMT2, BMI, cholesterol level, arterial
blood pressure. Due to a scarce number of studies available between-study variance 
was estimated using the REML method. The value of between-study variance evalu-
ated using a meta-regression model for retinopathy in DMT2 without covariates was 
0.4547. RESULTS: Inclusion of the difference between the intervention group and the
control group with respect to the HbA1c level resulted in decrease to 0.1572. There-
fore the covariate under consideration explains the heterogeneity in 65.4%. The 
obtained value of directional coefﬁ cient was statistically signiﬁ cant and equal to
0.5824, which means that increase of difference between the groups with HbA1c level 
by 1 unit results in increase of the logarithm of relative risk by 0.5824, reﬂ ecting 
increase the risk by 1.79 times. CONCLUSIONS: It was demonstrated using meta-
regression that the difference with respect to the HbA1c level is the cause of hetero-
geneity between the studies. Relative risk of development of retinopathy increases with 
increase of the difference in HbA1c level.
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OBJECTIVES: The clinical consequences and costs of medication errors (ME) have
signiﬁ cant implications on quality of care. A detailed understanding of the occurrence 
and patterns of MEs is critical to reducing ME rates and improving patient outcomes.
However, ME rates are often estimated inaccurately. ME rates are typically heteroge-
neous with respect to hospitals and units within hospitals, because of differences in 
health care provider (HCP) experience and skill. Although this heterogeneity has 
important implications for the precision and power of ME analysis, it is seldom taken
into account in the estimation of MEs. METHODS: To evaluate the effects of hetero-
geneity on the precision and power of estimated ME rates, we assumed three sources 
of heterogeneity: hospital, unit (or HCP) within hospital, and random error. We 
derived formulas representing the variances of the estimated ME rates and the vari-
ances of comparisons of ME rates, and graphically illustrated the effects of sample
sizes and magnitude of heterogeneity on the variances. RESULTS: The heterogeneity
associated with hospital and unit induces clustering of MEs within hospitals and units, 
increasing variability in the estimated ME rates compared with what would be 
observed in the absence of heterogeneity. Even in the presence of low levels of hetero-
geneity, the variances of the estimated ME rates can be substantially increased. Power 
associated with comparisons of ME rates also can be substantially affected with 
decreased power for comparisons between hospitals or units and increased power for 
comparisons within hospitals or units. CONCLUSIONS: Heterogeneity of MEs with 
respect to hospitals and hospital units (or HCPs) can have a substantial effect on preci-
sion and power, and should be incorporated in the analyses ME rates. We provide 
precision and power formulas for planning future studies of MEs.
